Medication-info.com Search Menu

Widaplik: Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx) Boxed warning
Strength:
10 mg, 1.25 mg, 0.625 mg, 20 mg, 2.5 mg, 1.25 mg, 40 mg, 5 mg, 2.5 mg
Drug class:
Active ingredients:
Similar drugs:

Source: FDA drug labeling via NLM DailyMed · About this document

Patient information: uses, side effects, how to take - Widaplik

What is the most important information I should know about Widaplik?

Widaplik can cause harm or death to an unborn baby. Talk to your healthcare provider about other ways to lower your blood pressure if you plan to become pregnant. If you get pregnant during treatment with Widaplik, stop taking Widaplik and tell your healthcare provider right away.

What is Widaplik?

Widaplik is a prescription medicine that contains telmisartan, amlodipine and indapamide.

Widaplik is used to treat high blood pressure (hypertension) in adults. Widaplik may be used as the first medicine to lower your high blood pressure if your healthcare provider decides you are likely to need more than one medicine.

It is not known if Widaplik is safe and effective in children.

Do not take Widaplik if you:

  • have no urine output (anuria).
  • are allergic to telmisartan, amlodipine, indapamide, or to other sulfonamide type medicines, or to any of the ingredients in Widaplik. See the end of this leaflet for a complete list of ingredients in Widaplik.
  • have diabetes and are taking aliskiren.

Before taking Widaplik, tell your healthcare provider about all of your medical conditions, including if you:

  • have liver problems
  • have kidney problems
  • have heart problems
  • have imbalance of salts (electrolytes) and fluids in your body
  • have glaucoma
  • have an allergy to the medicines sulfonamide or penicillin
  • have gout

  • are pregnant or plan to become pregnant. See “What is the most important information I should know about Widaplik?”

  • are breastfeeding or plan to breastfeed. It is not known if Widaplik passes into your breast milk. Do not breastfeed during treatment with Widaplik. Talk with your healthcare provider about the best way to feed your baby if you take Widaplik.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Widaplik may affect the way other medicines work, and other medicines may affect how Widaplik works.

Especially tell your healthcare provider if you take:

  • aliskiren
  • digoxin
  • lithium
  • non-steroidal anti-inflammatory drugs (NSAIDs)
  • simvastatin
  • cyclosporine or tacrolimus
  • norepinephrine

Know the medicines you take. Keep a list of them and show it to your healthcare provider or pharmacist when you get a new medicine.

How should I take Widaplik?

  • Take Widaplik exactly as your healthcare provider tells you to take it.
  • Your healthcare provider will tell you how much Widaplik to take and when to take it. Your healthcare provider may change your dose if needed.
  • Take Widaplik 1 time each day.
  • Swallow Widaplik tablets whole. Do not cut, crush, or chew tablets.

  • Take Widaplik with or without food.

  • If you take too much Widaplik, call your healthcare provider or go to the nearest hospital emergency room right away.

What are possible side effects of Widaplik?

Widaplik may cause serious side effects, including:

  • harm or death to your unborn baby. See “What is the most important information I should know about Widaplik ?”

  • low blood pressure (hypotension). Low blood pressure can happen with Widaplik, especially during the first few days of starting treatment and can cause you to feel lightheaded. If you feel lightheaded, faint, or dizzy call your healthcare provider right away. Low blood pressure is most likely to happen if you:

    • take water pills (diuretics)
    • are on a low-salt diet
    • do not drink enough liquids
    • sweat excessively
    • have heart problems
    • get sick with vomiting or diarrhea
  • changes in levels of body salt (electrolyte) and sugar (glucose) in your blood. Widaplik can cause low levels of sodium and magnesium in your blood and affect your blood glucose and potassium levels. Your healthcare provider will check your electrolyte and glucose levels during treatment with Widaplik. Do not use potassium supplements or salt substitutes that contain potassium without talking to your healthcare provider.

  • kidney problems. Widaplik can cause kidney problems that can lead to decreased urine output and short-term (acute) kidney failure. Kidney problems may get worse if you already have kidney disease. People with severe congestive heart failure have an increased risk of kidney problems. Your healthcare provider will check your kidney function during treatment with Widaplik. Tell your healthcare provider if you get:

    • swelling in your feet, ankles, or hands
    • unexplained weight gain

  • eye problems. One of the medicines in Widaplik can cause eye problems that may lead to vision loss. Symptoms of eye problems can happen within hours to weeks of starting Widaplik. Tell your healthcare provider right away if you have:

    • decrease in vision
    • eye pain
  • increased uric acid levels in your blood (hyperuricemia). People who have increased levels of uric acid in the blood may develop gout.

Rare, serious allergic reactions may happen. Tell your healthcare provider right away if you get any of these symptoms:

  • swelling of face, tongue, throat
  • difficulty breathing
  • rash or raised patches on your skin (hives)

The most common side effects of Widaplik include:

  • low blood pressure
  • low sodium and potassium levels in your blood

These are not all the possible side effects of Widaplik. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Widaplik?

  • Store Widaplik tablets at room temperature between 68°F to 77°F (20°C to 25°C).
  • Do not remove Widaplik tablets from bottle until right before you take them.
  • Keep Widaplik tablets out of the light and away from moisture.
  • Store Widaplik tablets in the original container.

Keep Widaplik and all medicines out of the reach of children.

General information about the safe and effective use of Widaplik.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Widaplik for a condition for which it was not prescribed. Do not give Widaplik to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Widaplik that is written for health professionals.

What are the ingredients in Widaplik?

Active ingredients: telmisartan, amlodipine besylate and indapamide.

Inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, meglumine, microcrystalline cellulose, polyvinyl pyrrolidone, pregelatinized starch, and sodium hydroxide.

Manufactured by: Piramal Pharma Limited, Plot No. 67-70, Sector II, Pithampur, Dist. Dhar, Madhya, Pradesh 454775, India

For more information, call Azurity Pharmaceuticals, Inc. at 1-800-461-7449 or visit www.widaplik.com.

This Patient Information has been approved by the U.S. Food and Drug Administration Revised: DEC/2025

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 219423 · View the label on DailyMed

Revision date stated in the text: December 2025

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Widaplik

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Boxed warning Yes – this drug has a boxed warning (also called a black box warning), the strongest warning of the FDA.
Drug class Angiotensin 2 Receptor Blocker, Calcium Channel Blocker, Dihydropyridine Calcium Channel Blocker, Thiazide-like Diuretic
Active ingredients Telmisartan, Amlodipine besylate, Indapamide
Dosage form Tablet
Route Oral
Marketing status listed in the FDA NDC Directory
Company (applicant) AZURITY
FDA approval NDA 219423New Drug Application (NDA) Approved June 5, 2025
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
10 mg, 1.25 mg, 0.625 mg – 30 in 1 bottle NDC 24338-001-30
20 mg, 2.5 mg, 1.25 mg – 30 in 1 bottle NDC 24338-002-30
40 mg, 5 mg, 2.5 mg – 30 in 1 bottle NDC 24338-003-30

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.